Abstract
Background: Echocardiography (ECHO)-determined tricuspid regurgitation jet velocity (TRV) ≥2.5 m/s occurs in about 30% of adults with sickle cell disease(SCD)and is associated with increased mortality. The frequency and significance of high TRV in children is not known. We determined the prevalence and risk factors of elevated estimated systolic pulmonary artery pressures in 228 patients with SCD and 39 controls.
Methods: Patients with SCD (Hb SS, SC, SB thalassemia or other major sickling phenotypes) aged 3 to 20 years were evaluated clinically and with ECHO and six minute walk tests at their steady state. Healthy, non-SCD controls, matched for ethnicity, sex and age, were also evaluated.
Results: A comparison of patients and controls is summarized in Table 1. 184 patients (81%) had hemoglobin SS phenotype and 28 (12%) had hemoglobin SC. TRV was measurable in 214 (94%) of the patients and 34 (87%) of the controls. In a multivariate logistic regression model, each 10 mm Hg increase in systolic blood pressure was associated with an estimated 2.0-fold increase in the odds of TRV≥2.5 m/sec (P = 0.002) and a 10-fold increase in LDH with a 25-fold increase in the odds (P = 0.015).
Conclusion: This study of children with SCD who have limited iron overload and limited renal dysfunction compared with the aging SCD population provides a unique window into the early pathogenesis of PH in SCD. TRV and LVMI are significantly higher in children and adolescents with SCD at steady state than age-matched control participants. Among children with SCD, TRV elevation is independently associated with systolic BP and LDH concentration. In this analysis we find a strong association with hemolysis and systemic hypertension and surprisingly no associations with vaso-occlusive events or biomarkers (VOC, ACS, HU use, WBC and platelet counts).
. | SCD(n=228) . | Control (n=39) . | p . |
---|---|---|---|
Age in years | 12 (5) | 12 (5) | 0.7 |
Female (%) | 48% | 46% | 0.8 |
Systolic BP (mm Hg) | 112 (11) | 116 (15) | 0.1 |
Diastolic BP (mm Hg) | 64 (9) | 68 (10) | 0.040 |
Six minute walk in meters | 454 (76) | 498 (84) | 0.006 |
TRV in m/sec | 2.3 (0.3) | 2.1 (0.3) | 0.003 |
TRV 2.5 m/sec (%) | 21% | 3% | 0.012 |
LV intern. diastolic diam Z-score | 1.2(1.4) | −0.3(1.2) | <0.001 |
LV mass index | 88 (25) | 59 (13) | <0.001 |
. | SCD(n=228) . | Control (n=39) . | p . |
---|---|---|---|
Age in years | 12 (5) | 12 (5) | 0.7 |
Female (%) | 48% | 46% | 0.8 |
Systolic BP (mm Hg) | 112 (11) | 116 (15) | 0.1 |
Diastolic BP (mm Hg) | 64 (9) | 68 (10) | 0.040 |
Six minute walk in meters | 454 (76) | 498 (84) | 0.006 |
TRV in m/sec | 2.3 (0.3) | 2.1 (0.3) | 0.003 |
TRV 2.5 m/sec (%) | 21% | 3% | 0.012 |
LV intern. diastolic diam Z-score | 1.2(1.4) | −0.3(1.2) | <0.001 |
LV mass index | 88 (25) | 59 (13) | <0.001 |
Variables . | TRV <2.5 (n= 169) . | TRV ≥2.5 (n=45) . | p . |
---|---|---|---|
History of acute chest syndrome (%) | 20% | 40% | 0.034 |
Hydroxyurea therapy | 42% | 44% | 0.8 |
Hemoglobin in g/dl | 9.3 (1.8) | 8.9 (1.7) | 0.071 |
LDH in U/L | 393 (163) | 474 (170) | 0.009 |
Total Bilirubin in mg/dL | 2.7 (1.9) | 3.8 (2.2) | 0.004 |
Variables . | TRV <2.5 (n= 169) . | TRV ≥2.5 (n=45) . | p . |
---|---|---|---|
History of acute chest syndrome (%) | 20% | 40% | 0.034 |
Hydroxyurea therapy | 42% | 44% | 0.8 |
Hemoglobin in g/dl | 9.3 (1.8) | 8.9 (1.7) | 0.071 |
LDH in U/L | 393 (163) | 474 (170) | 0.009 |
Total Bilirubin in mg/dL | 2.7 (1.9) | 3.8 (2.2) | 0.004 |
Author notes
Disclosure:Research Funding: Investigator in the Novartis Sponsored Phase II study of ICL-670(Exjade) in Sickle Cell Iron Overload Study.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal